Viridian Therapeutics to Webcast Veligrotug Phase 3 THRIVE-2 Topline Results on December 16, 2024

As an investor, I've always been drawn to the stability and predictability of "boring but lucrative" investments. While some may chase the thrill of options and risky stocks, I prefer the steady performance of companies like Morgan Stanley, which, despite being downgraded by Oppenheimer, continues to impress with its strong performance and stable credit quality improvements. This preference for stability extends to my interest in Viridian Therapeutics and its upcoming webcast of Veligrotug Phase 3 THRIVE-2 topline results on December 16, 2024.



The banking industry, much like the broader market, can be volatile and unpredictable. However, Morgan Stanley has stood out as a beacon of stability, transforming under the leadership of James Gorman. Gorman's strategic acquisitions, particularly in wealth management, have turned the bank into a reliable and profitable institution. This transformation highlights the value of stability and predictability in investments, as a "no-surprise" bank like Morgan Stanley deserves a higher valuation than its peers.



Viridian Therapeutics, with its Veligrotug Phase 3 THRIVE-2 trial, offers a similar opportunity for investors seeking stable and predictable growth. The company's previous THRIVE trial results were promising, with a 70% proptosis responder rate and significant improvements in diplopia and Clinical Activity Score (CAS). If the THRIVE-2 results align with these findings, Veligrotug could become a leading treatment for thyroid eye disease (TED), potentially transforming Viridian Therapeutics into a stable, profitable biopharmaceutical company.



The topline results of the Veligrotug Phase 3 THRIVE-2 trial could significantly impact Viridian Therapeutics' regulatory submission timeline and market access strategy. If the results demonstrate Veligrotug's efficacy and safety in treating chronic TED, Viridian could submit a Biologics License Application (BLA) to the FDA in the second half of 2025, as planned. Positive results may also accelerate market access by strengthening Viridian's position in negotiations with payers and healthcare providers.

In conclusion, as an investor who values stability and predictability, I am excited about the upcoming webcast of Veligrotug Phase 3 THRIVE-2 topline results. The potential of Veligrotug to become a leading treatment for TED, combined with Viridian Therapeutics' strong clinical trial data, makes this a compelling investment opportunity. I look forward to the results and the potential growth that this "boring but lucrative" investment could bring.